<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712266</url>
  </required_header>
  <id_info>
    <org_study_id>ABV201</org_study_id>
    <nct_id>NCT04712266</nct_id>
  </id_info>
  <brief_title>A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes</brief_title>
  <official_title>A Randomized, Double-blinded Trial to Investigate Glycemic Excursions Following an Oral Mixed Meal Challenge in Subjects With Type 1 Diabetes When Concomitantly Treated With Insulin Alone or Co-administered Insulin and Glucagon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abvance Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>T1D Exchange, United States</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abvance Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, double-blind, randomized trial in subjects with type 1 diabetes&#xD;
      mellitus applying an adaptive design approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were be studied on two occasions, in randomized sequence, whereby glycemic&#xD;
      excursions are assessed following an oral mixed meal challenge while treated with either&#xD;
      insulin alone or co-administered insulin and glucagon.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Actual">January 10, 2021</completion_date>
  <primary_completion_date type="Actual">December 15, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hypoglycemic excursions</measure>
    <time_frame>180-360 minutes post meal</time_frame>
    <description>&lt; 50mg/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hyperglycemic excursions</measure>
    <time_frame>60-120 minutes post meal</time_frame>
    <description>&gt;150mg/dl</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Type 1 Diabetes Mellitus With Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Insulin IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>calculated insulin rate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin and Glucagon IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>calculated molar ratio insulin:glucagon</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>calculated IV insulin:Glucagon molar ratio</description>
    <arm_group_label>Insulin and Glucagon IV</arm_group_label>
    <other_name>Glucagen Hypokit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>calculated IV Insulin dose infused at a constant rate</description>
    <arm_group_label>Insulin IV</arm_group_label>
    <arm_group_label>Insulin and Glucagon IV</arm_group_label>
    <other_name>Human Insulin (Eli Lilly)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged between 18 and 64 years (both inclusive)&#xD;
&#xD;
          -  Type 1 diabetes mellitus (as diagnosed clinically) ≥ 12 months prior to the screening&#xD;
             visit&#xD;
&#xD;
          -  Treated with daily insulin for T1DM ≥ 12 months prior to the screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Bode, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlanta Diabetes Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

